Skip to main content

Table 1 Clinical characteristics of patients with Crohn’s disease (N = 168)

From: Efficacy of early immunomodulator therapy on the outcomes of Crohn’s disease

Characteristics Early immuno-modulator therapy Conventional therapy P-value
Age, yr, median (IQR) 26.5 (11.0) 30 (12.3) 0.137
Sex, (%)    0.305
  Male 81 (79.4) 57 (86.4)  
  Female 21 (20.6) 9 (13.6)  
Activity status at start medication, (%)    0.474
  Remission 7 (6.9) 5 (7.6)  
  Mild 24 (23.5) 17 (25.8)  
  Moderate 70 (68.6) 41 (62.1)  
  Severe 1 (1.0) 3 (4.5)  
Location, (%)    0.191
  L1 (ileal) 9 (8.8) 2 (3.0)  
  L2 (colonic) 13 (12.7) 7 (10.6)  
  L3 (ileocolonic) 16 (15.7) 13 (19.7)  
  L4 (only upper GI) 0 (0) 3 (4.5)  
  NA 64 (62.8) 41 (62.2)  
Behavior at diagnosis, (%)    0.651
  B1 (non-stricturing, non-penetrating) 20 (19.6) 14 (21.2)  
  B2 (stricturing) 10 (9.8) 3 (4.6)  
  Perianal disease 8 (7.8) 8 (12.1)  
  NA 64 (62.8) 41 (62.1)  
Initial medication, (%)    <0.001
  Only 5-ASA 54 (52.9) 56 (84.8)  
  5-ASA with steroids 9 (8.8) 10 (15.2)  
  Only immunomodulators 3 (2.9) 0 (0)  
  Immunomodulators with 5-ASA 36 (35.3) 0 (0)  
CDAI, median (IQR) 263.0 (119.5) 249.2 (117.9) 0.643
BMI, median (IQR) 19.8 (4.7) 18.9 (3.7) 0.141
CRP, median (IQR) 8.1 (39.2) 8.9 (24.8) 0.052
ESR, median (IQR) 54.0 (59.0) 55.0 (52.0) 0.462
Hct, median (IQR) 38.4 (8.6) 37.3 (7.2) 0.905
  1. IQR, inter-quartile range; CDAI, Crohn’s disease activity index; BMI, body mass index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Hct, hematocrit; NA, not applicable.